journal
MENU ▼
Read by QxMD icon Read
search

Cancer Chemotherapy and Pharmacology

journal
https://www.readbyqxmd.com/read/28429051/induction-chemotherapy-followed-by-concurrent-chemoradiotherapy-vs-concurrent-chemoradiotherapy-for-locoregionally-advanced-nasopharyngeal-carcinoma-a-retrospective-cohort-study
#1
Jianyuan Zhang, Shaojun Chen, Guisheng Li, Weihua Zhang, Tingting Qin, Ping Yin, Haixin Huang, Hongwei Jiang
PURPOSE: To evaluate the efficacy and toxicity of induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: We reviewed data of locoregionally advanced NPC patients who underwent 2 different treatment plans, 1 with induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) and the other with only concurrent chemoradiotherapy (CCRT). All patients received cisplatin 80 mg/m(2) 3 weeks one cycle concurrently with intensity-modulated radiation therapy, and three IC protocols were included for the IC + CCRT group...
April 20, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28424965/assessment-of-drug-drug-interaction-potential-between-ceritinib-and-proton-pump-inhibitors-in-healthy-subjects-and-in-patients-with-alk-positive-non-small-cell-lung-cancer
#2
Yvonne Y Lau, Wen Gu, Tiffany Lin, Kalyanee Viraswami-Appanna, Can Cai, Jeffrey W Scott, Michael Shi
PURPOSE: The impact of proton pump inhibitors (PPIs) on the pharmacokinetics (PK) and efficacy of ceritinib was evaluated. METHODS: A healthy subject drug-drug interaction (DDI) study was conducted to assess the effect of esomeprazole on the PK of a single 750 mg dose of ceritinib. To further investigate the impact of PPIs on the PK and efficacy of ceritinib in ALK-positive cancer patients, two subgroup analyses were performed. Analysis 1 evaluated ceritinib steady-state trough concentration (Ctrough,ss) and overall response rate (ORR) by concomitant use of PPIs in patients from the ASCEND-1, -2, and -3 studies; analysis 2 evaluated ceritinib single-dose and steady-state AUC0-24h and C max by concomitant PPI use in patients from ASCEND-1 using a definition of PPI usage similar to that used in the healthy subject study...
April 19, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28424964/pharmacodynamic-effects-in-the-cerebrospinal-fluid-of-rats-after-intravenous-administration-of-different-asparaginase-formulations
#3
Andrea Ballerini, Federico Moro, Ilaria Fuso Nerini, Claudio Marcello Marzo, Angelo Di Clemente, Mariella Ferrari, Maurizio D'Incalci, Andrea Biondi, Antonella Colombini, Valentino Conter, Luca Porcu, Luigi Cervo, Carmelo Rizzari, Massimo Zucchetti
PURPOSE: Asparaginase (ASNase) is used to treat various hematological malignancies for its capacity to deplete asparagine (ASN) in serum and cerebrospinal fluid (CSF). Since the biological mechanisms underlying CSF asparagine depletion in humans are not yet fully elucidated, this study compared, for the first time, the pharmacological properties of three clinically used ASNase formulations in a rodent model. METHODS: Male Wistar rats were treated with E.coli-ASNase, PEG-ASNase, or ERW-ASNase at different doses...
April 19, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28424963/pharmacokinetics-and-safety-of-carfilzomib-in-patients-with-relapsed-multiple-myeloma-and-end-stage-renal-disease-esrd-an-open-label-single-arm-phase-i-study
#4
Hang Quach, Darrell White, Andrew Spencer, P Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger
PURPOSE: The pharmacokinetics (PK) of carfilzomib have been previously studied in multiple myeloma patients with varying degrees of renal impairment (normal, mild, moderate, severe, and end-stage renal disease [ESRD]) at doses of 15 and 20 mg/m(2). This study evaluated carfilzomib PK at higher doses of 27 and 56 mg/m(2) in normal renal function and ESRD patients. METHODS: Patients received carfilzomib on two consecutive days/week for 3 weeks every 28-day cycle: 20 mg/m(2) (cycle 1 day 1-2), escalated to 27 mg/m(2) on cycle 1 day 8; if tolerated, 56 mg/m(2) starting cycle 2 day 1...
April 19, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28424962/phase-i-dose-escalation-study-of-milciclib-in-combination-with-gemcitabine-in-patients-with-refractory-solid-tumors
#5
Sandrine Aspeslagh, Kunwar Shailubhai, Rastilav Bahleda, Anas Gazzah, Andréa Varga, Antoine Hollebecque, Christophe Massard, Anna Spreafico, Michele Reni, Jean-Charles Soria
BACKGROUND: This phase I trial evaluated the safety and tolerability of milciclib, an inhibitor of multiple cyclin-dependent kinases and tropomycin receptor kinase A, in combination with gemcitabine in patients with refractory solid tumors. DESIGN: Sixteen patients were enrolled and treated with milciclib at three dose levels (45 mg/m(2)/day, n = 3; 60 mg/m(2)/day, n = 3; and 80 mg/m(2)/day, n = 10) with a fixed dose of gemcitabine (1000 mg/m(2)/day). Milciclib was administered orally once daily for 7 days on/7 days off in a 4-week cycle, and gemcitabine was administered intravenously on days 1, 8 and 15 in a 4-week cycle...
April 19, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28421294/a-prospective-comparison-of-intra-arterial-chemotherapy-combined-with-intravesical-chemotherapy-and-intravesical-chemotherapy-alone-after-transurethral-resection-with-a-thulium-laser-in-high-risk-non-muscle-invasive-bladder-cancer
#6
Feng Sun, Ruizhe Zhao, Yiyong Zhu, Di Cui, Xiaohai Wang, Bangmin Han, Shengjie Liang, Haitao Liu, Xiaowen Sun, Fujun Zhao, Dongliang Xu, Shujie Xia
Objective To compare intra-arterial chemotherapy combined with intravesical chemotherapy with intravesical chemotherapy alone in the treatment of high-risk non-muscle invasive bladder cancer (HRBC) after thulium laser resection of a bladder tumor (TmLRBT). MATERIALS AND METHODS: From January 2009 to December 2013, 283 patients with HRBC were randomly assigned to the combined group (group A, n = 141) or intravesical chemotherapy-alone group (group B, n = 142) after TmLRBT. Intra-arterial chemotherapy was administered after initial TmLRBT, with 3 courses at 4-week intervals...
April 18, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28417167/gene-expression-levels-of-gamma-glutamyl-hydrolase-in-tumor-tissues-may-be-a-useful-biomarker-for-the-proper-use-of-s-1-and-tegafur-uracil-leucovorin-in-preoperative-chemoradiotherapy-for-patients-with-rectal-cancer
#7
Sotaro Sadahiro, T Suzuki, A Tanaka, K Okada, G Saito, H Miyakita, T Ogimi, H Nagase
PURPOSE: Preoperative chemoradiotherapy (CRT) using 5-fluorouracil (5-FU)-based chemotherapy is the standard of care for rectal cancer. The effect of additional chemotherapy during the period between the completion of radiotherapy and surgery remains unclear. Predictive factors for CRT may differ between combination chemotherapy with S-1 and with tegafur-uracil/leucovorin (UFT/LV). METHODS: The subjects were 54 patients with locally advanced rectal cancer who received preoperative CRT with S-1 or UFT/LV...
April 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28396940/adjunction-of-a-mek-inhibitor-to-vemurafenib-in-the-treatment-of-metastatic-melanoma-results-in-a-60-reduction-of-acute-kidney-injury
#8
Cécile Teuma, Solenne Pelletier, Mona Amini-Adl, Marie Perier-Muzet, Delphine Maucort-Boulch, Luc Thomas, Maurice Laville, Denis Fouque, Stéphane Dalle
INTRODUCTION: A combined therapy MEK inhibitor, Cobimetinib (CB) and BRAF inhibitor, Vemurafenib (VMF), results in an improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma. VMF skin adverse effects attributed to ERK paradoxical activation are decreased by the adjunction of CB. The aim of this study was to determine if this combination also improved the renal side effects of VMF. PATIENTS AND METHODS: To investigate the incidence of acute kidney injury (AKI), we conducted a retrospective observational monocentric study in Lyon Sud University Hospital in France...
April 10, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28393257/luteolin-induces-apoptosis-by-ros-er-stress-and-mitochondrial-dysfunction-in-gliomablastoma
#9
Qiang Wang, Handong Wang, Yue Jia, Hao Pan, Hui Ding
OBJECTIVE: Luteolin, a common dietary flavonoid, induces apoptosis of many types of cancer cells. However, its role in glioblastoma and the potential mechanisms remain unknown. In this research, we studied the molecular mechanisms of the anti-cancer effect of luteolin in glioblastoma cancer cell lines. METHODS: Both U251MG and U87MG human glioblastoma cell lines were tested. Cell growth was assessed by the cell counting kit-8. Cell apoptosis was detected with flow cytometry and caspase-3 immunofluorescence staining...
April 9, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28391355/comparison-between-hypersensitivity-reactions-to-cycles-of-modified-folfox6-and-xelox-therapies-in-patients-with-colorectal-cancer
#10
Hideki Ohta, Takahiro Hayashi, Sumie Murai, Hideyo Shiouchi, Yosuke Ando, Satomi Kumazawa, Kaori Ito, Yoshiaki Ikeda, Hiroshi Matsuoka, Kotaro Maeda, Kenji Kawada, Kimio Yasuda, Shigeki Yamada
PURPOSE: Although hypersensitivity reactions (HSRs) to oxaliplatin (L-OHP) therapy are well-documented, few reports have compared different therapies in terms of HSR occurrence. In this study, we compared the frequency and pattern of HSRs to modified FOLFOX6 (mFOLFOX6; 5-fluorouracil, levofolinate calcium and L-OHP infusions) and XELOX (capecitabine and L-OHP) therapies, and sought to identify risk factors associated with HSRs. METHODS: Patients who had received mFOLFOX6 or XELOX chemotherapeutic regimens for unresectable colon or rectal cancer or as adjuvant chemotherapy following colon cancer surgery between April 2012 and August 2015 were included...
April 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28391354/low-plasma-concentration-of-gefitinib-in-patients-with-egfr-exon-21-l858r-point-mutations-shortens-progression-free-survival
#11
Yuji Okuda, Kazuhiro Sato, Kazuhisa Sudo, Yukiyasu Hasegawa, Mariko Asano, Hajime Miura, Masahide Takeda, Masaaki Sano, Hiroyuki Watanabe, Hiroyuki Kobayashi, Takenori Niioka, Masatomo Miura, Hiroshi Ito
PURPOSE: The relationship between the pharmacokinetics and effects of gefitinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is unknown. In this study, we examined the correlation between gefitinib plasma concentration and progression-free survival (PFS) in patients with two common types of EGFR mutations: a deletion in exon 19 and point mutations in exon 21 L858R. METHODS: The retrospective analysis examined 40 patients who were administered 250 mg of gefitinib daily...
April 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28391353/wbp2-modulates-g1-s-transition-in-er-%C3%A2-breast-cancer-cells-and-is-a-direct-target-of-mir-206
#12
Yong-Qiang Ren, Hui-Jun Wang, Yong-Qing Zhang, Yan-Bing Liu
PURPOSE: The mechanisms underlying the oncogenic properties of WW domain binding protein 2 (WBP2) in breast cancer have not been fully understood. In this study, we explored the role of WBP2 in cell cycle regulation in ER+ breast cancer cells and how it is regulated in the cancer cells. METHODS: The association between WBP2 expression and prognosis in ER+ breast cancer was assessed by data mining in Breast Cancer Gene-Expression Miner v4.0. Cell cycle was assessed by PI staining and flow cytometry...
April 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28391352/the-impact-of-a-solitary-kidney-on-tolerability-to-gemcitabine-plus-cisplatin-chemotherapy-in-urothelial-carcinoma-patients-a-retrospective-study
#13
Masahiro Kondo, Yuji Hotta, Ryosuke Ando, Takahiro Yasui, Kazunori Kimura
PURPOSE: There is little information on tolerability to cisplatin-based chemotherapies in patients with a solitary kidney after nephroureterectomy. We evaluated the impact of having a solitary kidney on tolerability to gemcitabine plus cisplatin (GC) chemotherapy in urothelial carcinoma patients. METHODS: We retrospectively reviewed medical records of patients treated between August 2007 and November 2015. Eligible patients had received GC as first-line chemotherapy, including as neoadjuvant and adjuvant treatment...
April 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28391351/curcumin-inhibits-prostate-cancer-by-targeting-pgk1-in-the-foxd3-mir-143-axis
#14
Hongwen Cao, Hongjie Yu, Yigeng Feng, Lei Chen, Fang Liang
PURPOSE: Curcumin is a potent antitumor agent. The objective of this study was to explore the interaction between curcumin and PGK1, an oncogene in the FOXD3/miR-143 axis, in prostate cancer therapy. METHODS: MiRNA microarray analysis was used to identify miRNAs upregulated by curcumin treatment. MiR-143 was dramatically upregulated by curcumin. Cells were treated with antimiR-143 in combination to curcumin, followed by examining cell viability and migration. Bioinformatics analysis was used to investigate target genes of miR-143...
April 8, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28389780/computed-determination-of-the-in-vitro-optimal-chemocombinations-of-sphaeropsidin-a-with-chemotherapeutic-agents-to-combat-melanomas
#15
Aude Ingels, Carina Dinhof, Abhishek D Garg, Lucia Maddau, Marco Masi, Antonio Evidente, Walter Berger, Bieke Dejaegher, Véronique Mathieu
PURPOSE: Evasion to new treatments of advanced melanoma is still associated with a poor prognosis. Choosing the best combination of agents that can bypass resistance mechanisms remains a challenge. Sphaeropsidin A (Sph A) is a fungal bioactive secondary metabolite previously shown to force melanoma cells to undergo apoptosis via cell volume dysregulation. This work studied its in vitro combination with cytotoxic chemotherapeutics in a rational manner. METHODS: Four melanoma cell lines harboring different sensitivity levels to pro-apoptotic stimuli were used to build a predictive response surface model allowing the determination of the optimal in vitro combinations of Sph A with two drugs, i...
April 7, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28378028/up-regulation-of-autophagy-is-a-mechanism-of-resistance-to-chemotherapy-and-can-be-inhibited-by-pantoprazole-to-increase-drug-sensitivity
#16
Qian Tan, A M Joshua, M Wang, R G Bristow, B G Wouters, C J Allen, Ian F Tannock
BACKGROUND: Autophagy is a survival mechanism that allows recycling of cellular breakdown products, particularly in stressed cells. Here we evaluate the hypotheses that up-regulation of autophagy is a common mechanism of resistance to chemotherapy, and that drug resistance can be reversed by inhibiting autophagy with a proton pump inhibitor. METHODS: We exposed human PC3, LNCaP and MCF7 cells to seven clinically-used chemotherapy drugs ± pantoprazole, examined the up-regulation of autophagy and the effect on cellular proliferation by Western Blots, MTS assay and colony-forming assay...
April 4, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28378027/a-phase-ii-trial-of-neoadjuvant-chemoradiotherapy-with-intensity-modulated-radiotherapy-combined-with-gemcitabine-and-s-1-for-borderline-resectable-pancreatic-cancer-with-arterial-involvement
#17
Yuichi Nagakawa, Yuichi Hosokawa, Hidetsugu Nakayama, Yatsuka Sahara, Chie Takishita, Tetsushi Nakajima, Yousuke Hijikata, Kazuhiko Kasuya, Kenji Katsumata, Koichi Tokuuye, Akihiko Tsuchida
PURPOSE: Chemoradiotherapy using intensity-modulated radiotherapy (IMRT) is expected to provide a powerful alternative to conventional chemotherapy with a low incidence of adverse events. This study evaluated the efficacy of intensity modulated radiotherapy in combination with gemcitabine and S-1 as neoadjuvant chemoradiotherapy (NACRT) for borderline-resectable pancreatic cancer with arterial involvement (BR-A). METHODS: A total of 27 patients with BR-A were enrolled in this study between February 2012 and September 2015...
April 4, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28364288/co-administration-of-proton-pump-inhibitors-ameliorates-nephrotoxicity-in-patients-receiving-chemotherapy-with-cisplatin-and-fluorouracil-a-retrospective-cohort-study
#18
Kenji Ikemura, Kosuke Oshima, Tomoyuki Enokiya, Akiharu Okamoto, Hiroyasu Oda, Toshiro Mizuno, Hajime Ishinaga, Yuichi Muraki, Takuya Iwamoto, Kazuhiko Takeuchi, Naoyuki Katayama, Masahiro Okuda
PURPOSE: The nephrotoxicity of cisplatin (CDDP) is its dose-limiting side effect, and is caused by renal accumulation of CDDP mainly via organic cation transporter 2 (OCT2). Because proton pump inhibitors (PPIs) are known to inhibit OCT2 activity, PPI might ameliorate CDDP-induced nephrotoxicity. In the present study, we retrospectively investigated the effect of co-administration of PPI on CDDP-induced nephrotoxicity. METHODS: We analyzed the impact of PPI on the development of nephrotoxicity in 133 patients who received CDDP and fluorouracil (5-FU) therapy for the treatment of esophageal cancer or head and neck cancer...
March 31, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28361167/potential-drug-drug-interactions-with-abiraterone-in-metastatic-castration-resistant-prostate-cancer-patients-a-prevalence-study-in-france
#19
Clément Bonnet, Pascaline Boudou-Rouquette, Esther Azoulay-Rutman, Olivier Huillard, Jean-Louis Golmard, Edith Carton, Gaëlle Noé, Michel Vidal, Galdric Orvoen, Anne Chah Wakilian, Clémentine Villeminey, Benoit Blanchet, Jérôme Alexandre, François Goldwasser, Audrey Thomas-Schoemann
PURPOSE: Abiraterone acetate combined with prednisone improves survival in metastatic castration-resistant prostate cancer (mCRPC) patients. This oral anticancer agent may result in drug-drug interactions (DDI). We aimed to evaluate the prevalence of DDI with abiraterone and the possible determinants for the occurrence of these DDI. METHODS: We performed a single centre retrospective review from electronic medical records of mCRPC patients treated with abiraterone from 2011 to 2015...
March 30, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28357533/increased-ceramide-production-sensitizes-breast-cancer-cell-response-to-chemotherapy
#20
Jing Che, Yu Huang, Chuanrui Xu, Peng Zhang
BACKGROUND: Advanced breast cancer remains clinically challenging due to its resistance to chemotherapy. To understand the underlying mechanisms of resistance and identify drugable target, the involvement of ceramide metabolism is investigated. METHODS: Ceramide levels in breast cancer tissues derived from 30 patients with stage IV breast cancer before and after chemotherapy were analyzed using liquid chromatography mass spectrometry. mRNA and protein levels of ceramide enzymes were examined using western blot and QRT-PCR...
March 29, 2017: Cancer Chemotherapy and Pharmacology
journal
journal
27426
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"